canakinumab

Ligand id: 6773

Name: canakinumab

No information available.
Summary of Clinical Use
Used to treat rheumatic diseases; familial cold autoinflammatory syndrome (FCAS) [3] and Muckle-Wells syndrome (MWS) in patients >4 years of age, and systemic juvenile idiopathic arthritis (sJIA) in patients >2 years old [6].
Mechanism Of Action and Pharmacodynamic Effects
A monoclonal antibody which binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors [1], but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). The patent claiming this antibody, US7446175, reports that the antigenic epitope on IL-1β is the loop containing the Glu64 residue in the mature cytokine (equivalent to residue 180 of the precursor peptide) [2]
External links